PREPARATION AND DRUG RELEASE CHARACTERISTICS OF PINGYANGMYCIN GELATIN MICROSPHERES FOR EMBOLIZATION THERAPY

Objective: To prepare Pingyangmycin gelatin microspheres (PYM-GMS) for carotid artery embolization therapy and to study the release characteristics in vivo and in vitro. Methods: PYM-GMS was prepared by optical double-phase emulsified condensation polymerization. Through UV-spectrophotometer drug content and encapsulation rate were measured. The characteristics of drug release in vitro which could simulate the actual state in vivo were tested by HPLC. Three ways of vein drop, artery perfusion and artery embolization were contrasted. Under the supervision of X-ray, PYM-GMS were perfused into the external carotid artery of rabbits by superselective artery embolization. Blood samples were tested at different time and analyzed statistically. Results: The roundness of PYM-GMS was 1.02?.005. The mean diameter was 85.6 mm, 78% of them ranging from 50-200 mm, which fitted the use of embolization. PYM content and encapsulation rate were 6.8% and 91.3% respectively. 70% of the drug was released in 3 h in the simulated environment in vivo and total drug was released after more than 6 h. After artery embolization with small dosage of PYM-GMS, the local drug concentration was 8 times higher than the blood drug concentration and the high level of local drug concentration was kept for more than 120 min. Conclusion: External carotid artery embolization with PYM-GMS, which significantly reduced the circulating drug level and employment dosage, could prolong the duration higher drug concentration and suit the purpose of targeted tumor therapy.

Positional release techniques as a diagnostic-therapeutic approach in physiotherapy

Manual Therapy is a rehabilitative approach based on the use of therapeutic procedures that includes several techniques, but this paper focuses on what is known as Positional Release (PR), a therapeutic model that includes a series of manoeuvres that are mainly used for the treatment of soft tissue. A deeper understanding of this type of therapeutic approach, especially its well known and widespread variant, Strain-Counterstrain, could, through controlled trials and systematic reviews, confirm its effectiveness, definitively explain the neurophysiological mechanism, and therefore make Positional Release another indispensable option in the professional expertise of the physiotherapist.

Cytokine release syndrome complicated with rhabdomyolysis after chimeric antigen receptor T-cell therapy:A case report

BACKGROUND Chimeric antigen receptor T-Cell(CAR-T)therapy is an effective new treatment for hematologic malignancies.Cytokine release syndrome(CRS)and neurologic toxicity are main toxicities.CRS-induced rhabdomyolysis(RM)followed by CART therapy treatment has not been previously reported.CASE SUMMARY We report a case of a 22-year-old woman with relapsed acute lymphoblastic leukemia obtained sequential cluster of differentiation(CD)19 and CD22 CAR-T infusion.This patient experienced grade 3 CRS with RM,mild hypotension requiring intravenous fluids,and mild hypoxia and was managed effectively with the IL-6 receptor antagonist tocilizumab.This patient had no signs of immune effector cell-associated neurologic syndrome.Restaging scans 30 d postCAR-T therapy demonstrated a complete remission,and the symptoms of muscle weakness improved through rehabilitation.CONCLUSION Myalgia is an easily overlooked symptom of severe CRS after CAR-T therapy.It is necessary to monitor myoglobin levels when a patient presents with symptoms of myalgia or acute renal insufficiency.

Polymeric microneedle-mediated sustained release systems: Design strategies and promising applications for drug delivery

Parenteral sustained release drug formulations, acting as preferable platforms for longterm exposure therapy, have been wildly used in clinical practice. However, most of these delivery systems must be given by hypodermic injection. Therefore, issues including needle-phobic, needle-stick injuries and inappropriate reuse of needles would hamper the further applications of these delivery platforms. Microneedles (MNs) as a potential alternative system for hypodermic needles can benefit from minimally invasive and self-administration. Recently, polymeric microneedle-mediated sustained release systems (MN@SRS) have opened up a new way for treatment of many diseases. Here, we reviewed the recent researches in MN@SRS for transdermal delivery, and summed up its typical design strategies and applications in various diseases therapy, particularly focusing on the applications in contraception, infection, cancer, diabetes, and subcutaneous disease. An overview of the present clinical translation difficulties and future outlook of MN@SRS was also provided.

The effect of fluorouracil controlled release formulation in the treatment of 32 cases with advanced colorectal cancer by local implant

Objective: The aim of our study was to probe into the effect of fluorouracil controlled release formulation in the local implant treatment of patients with advanced colorectal cancer. Methods: Sixty-four cases of patients advanced colorectal cancer from August 2004 to February 2008 were selected for radical surgery, including 32 cases injected with intraoperative fluorouracil controlled release formulation in local implantation for 600 mg (the treatment group). Patients in another 32 cases received abdominal washing surgery by distilled water (the control group). All patients were followed up for 2 years and observed in aspects of the toxicity, 2-year survival rate, local recurrence rate and distant metastasis rate. Results: The 2-year survival rate and local recurrence rate in the treatment group was better than those in the control group (P < 0.05); as for toxicity and distant metastasis rate, no significant difference was observed. Conclusion: The effect of fluorouracil controlled release formulation in local implantation treatment was significant and the patient tolerance was satisfactory. Thus, it is an effective approach in the treatment of advanced colorectal cancer.

Study of targeted and controlled release of 5-fluorouracil-loaded PLA nanoparticles and microspheres on treatment of gastric tumor

The aim of this paper was to evaluate controlled release behavior and the therapeutic efficacy of 5-FU-loaded Poly(lactic acid) (PLA)microspheres to human gastric cancer xenograft, and the targeting effect of VEGF/5-FU loaded PLA nanoparticles. 5-FU-loaded PLA microspheres were prepared by an emulsion evaporation method, and were characterized by scanning electron microscopy (SEM). 5-FU loaded PLA nanoparticles were characterized by (TEM), and particle size analyzer determined the distribution of nanoparticles size. The release performances of 5-FU microspheres in vitro were studied in PH 7.4 phosphate buffered saline. The therapeutic efficacy of 5-FU-loaded PLA microspheres in vivo were studied using MGC-803 (human stomach cancer) xenograft. 32 nude mice were divided into four groups (n =8), 5-FU loaded PLA microspheres were injected at tumor site. VEGF121 monoclonal antibody was connected with 5-FU loaded PLA nanoparticles through carbodimide. The targeted effect of VEGF 5-FU loaded nanoparticles in vivo were observed by single photon emission computed tomography (SPECT) after tail vein injection at 1 h and 2 h. SEM observation showed that microspheres were spherical, and the diameters of two kinds of microspheres were 1 μm and 5 μm respectively. The mean diameter of nanoparticles was 191.0 nm, and the index of polydispersity was 0.202. The drug was released following biphasic kinetics, initial burst and the following steady phase. 1 μm and 5 μm 5-FU-loaded microspheres both resulted in increased life span (1 μm microspheres median survival time=40.63 days, 5 μm microspheres median survival time=62.25 days), against 5-FU pure drug (median survival time=14.5 days). These results strongly suggest that 5-FU-loaded PLA microspheres increase life span of nude mice bearing MGC-803 tumors. After injection for 2 h, almost all the VEGF/5-FU loaded PLA nanoparticles could centralize at the human gastric cancer xenograft sites. That demonstrated VEGF monoclonal antibody remain its bioactivity after connection with nanoparticles, VEGF/5-FU loaded PLA nanoparticles had very exact targeting function for gastric tumor xenograft.

疏风泄腑推拿法联合布洛芬混悬滴剂(美林)治疗小儿外感发热的临床疗效观察

目的:观察疏风泄腑推拿法联合布洛芬混悬滴剂(美林)口服治疗小儿外感发热的临床疗效,探讨疏风泄腑推拿法对发热患儿即刻退热的有效性。方法:选取2021年12月—2023年9月广州中医药大学东莞医院发热门诊及急诊科就诊的明确诊断为小儿外感发热的120例高热患者,随机分为试验组和对照组,每组60例。试验组采用疏风泄腑推拿法联合布洛芬混悬滴剂(美林)口服治疗,对照组单纯应用口服布洛芬混悬滴剂(美林)治疗,首次治疗1 d内多次随访。观察治疗前、治疗后30 min,1 h,2 h,3 h,4 h患者各时间节点体温,并记录体温的下降程度、治疗后24 h内使用布洛芬混悬滴剂(美林)的次数及再次使用布洛芬混悬滴剂(美林)间隔时间、治疗前后中医证候评分以及发生的不良事件。结果:(1)与治疗前比较,对照组及试验组患者治疗30 min,1 h,2 h,3 h,4 h后体温均降低,差异有统计学意义(P<0.05);治疗30 min后,试验组患者较对照组体温降低不明显,差异无统计学意义(P>0.05);治疗1 h、2 h、3 h、4 h后,试验组患者体温低于对照组,差异均有统计学意义(P<0.05);(2)治疗1 d后,试验组患者治疗总有效率(96.49%)明显高于对照组治疗总有效率(82.76%),差异有统计学意义(P<0.05);(3)治疗后,两组患者中医证候评分均较治疗前明显降低,且试验组中医证候评分降低更明显,差异有统计学意义(P<0.05);(4)研究过程中,两组患儿均未出现惊厥抽搐、药物不良反应,试验组患儿也未出现推拿后的皮肤、肌肉损伤等情况,因此,可认为疏风泄腑推拿法安全可靠。结论:疏风泄腑推拿法联合布洛芬混悬滴剂(美林)治疗在增大退热幅度、延长退热持续时间、减少1 d内布洛芬混悬滴剂(美林)使用次数、缓解其他伴随症状等方面优于单纯使用布洛芬混悬滴剂(美林)治疗。

基于超分子纳米递送系统的精准医疗研究进展

癌症已成为全球公共卫生安全的最主要威胁之一,严重危害人类的健康和生命安全.现行的多元化抗肿瘤疗法(如化疗、放疗、光疗和免疫疗法等)已取得重大临床研究进展,但其严重的毒副作用以及不可控的药物释放行为等因素往往导致抗肿瘤疗效不佳.因此,如何有效精准递送药物实现按需给药,并缓解对正常组织的不良反应是临床研究亟待解决的难题.近年来,纳米药物递送系统由于其高载药量、低毒副作用、可控的药物释放性能以及良好的靶向性等优点备受关注.其中,基于超分子化学组装的纳米递送体系具有独特的动态可调谐相互作用,使得其对环境的微小变化较为敏感,有利于实现其在肿瘤病灶部位的受控形变,从而达到药物控释的目的,实现精准医疗.本文综合评述了超分子纳米递送系统的最新进展,包括不同类型的超分子纳米递送体系的构建、超分子纳米递送系统的药物控释策略以及超分子纳米递送系统的生物应用.最后,探讨了超分子纳米递送系统的精准医疗前景和关键挑战.

Enhanced boron neutron capture therapy(BNCT)through controlled drug release via boron-loaded nanofiber mats

Boron neutron capture therapy(BNCT)is a novel binary therapy combining boron targeted drugs and neutron irradiation,which can selectively and effectively kill cancer cells at the cellular scale.Controlled release of boron drug and its accumulation in tumor sites are the crux of BNCT.Here,we developed a^(10)B-boric acid(^(10)BA)-loaded nanofiber applying for BNCT by in situ administration.The nanofibers were obtained by electrospinning technique using polyethylene glycol/polylactide(PEO/PLA)block copolymers.By changing the ratio of hydrophilicity to hydrophobicity of the nanofibers,the controlled release and the effective accumulation of boron 10 isotope(^(10)B)were achieved in situ.The^(10)B content in tumor could reach to 2540μg/g,significantly exceeding the required level of 20–50μg/g for BNCT operation.Utilizing pertinent DNA damage experiments,direct evidence and quantified data of BNCT-induced DNA damage in tumor cells were obtained for the first time.Transcriptome sequencing was employed to predict the molecular mechanisms and potential signaling pathways of BNCT,providing theoretical basis for future combined therapies.The antitumor efficiency of BNCT was demonstrated by establishing mice model of subcutaneous tumor and tumor recurrence.The research presents a novel boron-loaded nanofiber mats for BNCT,which enables controlled drug release and holds significant potential in the treatment of unresectable or postoperative residual tumors.

雌激素反向添加疗法联合促性腺激素释放激素激动剂治疗腹腔镜术后子宫内膜异位症患者的效果

目的:观察雌激素反向添加疗法联合促性腺激素释放激素激动剂(GnRH-a)治疗腹腔镜术后子宫内膜异位症(EMT)患者的效果。方法:回顾性分析2020年7月至2022年4月于该院行腹腔镜手术的136例EMT患者的临床资料,根据治疗方法不同将其分为对照组和观察组各68例。术后,对照组给予GnRH-a治疗,观察组在对照组基础上联合雌激素反向添加疗法治疗。比较两组治疗前后性激素指标[卵泡刺激素(FSH)、雌二醇(E_(2))、黄体生成素(LH)]、卵巢储备功能指标[窦卵泡数目、卵子数目、抗米勒管激素(AMH)]水平,不良反应发生率,以及复发率。结果:治疗后,两组FSH、E_(2)、LH水平均低于治疗前,但观察组高于对照组,差异有统计学意义(P<0.05);两组窦卵泡数、卵子数、AMH水平均低于治疗前,但观察组高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为4.41%(3/68),低于对照组的14.71%(10/68),差异有统计学意义(P<0.05);术后6、12、18个月,两组复发率比较,差异均无统计学意义(P>0.05)。结论:雌激素反向添加疗法联合GnRH-a治疗腹腔镜术后EMT患者可调节机体性激素指标水平,维护卵巢储备功能,降低不良反应发生率,效果优于单纯GnRH-a治疗。

Current multifunctional albumin-based nanoplatforms for cancer multi-mode therapy

Albumin has been widely applied for rational design of drug delivery complexes as natural carriers in cancer therapy due to its distinct advantages of biocompatibility,abundance,low toxicity and versatile property.Hence,various types of multifunctional albumin-based nanoplatforms(MAlb-NPs)that adopt multiple imaging and therapeutic techniques have been developed for cancer diagnosis and treatment.Stimuli-responsive release,including reduction-sensitive,p H-responsive,concentration-dependent and photodynamic-triggered,is important to achieve low-toxicity cancer therapy.Several types of imaging techniques can synergistically improve the effectiveness of cancer therapy.Therefore,combinational theranostic is considered to be a prospective strategy to improve treatment efficiency,minimize side effects and reduce drug resistance,which has received tremendous attentions in recent years.In this review,we highlight several stimuli-responsive albumin nanoplatforms for combinational theranostic.

Kinetics of testosterone recovery in clinically localized prostate cancer patients treated.with radical prostatectomy and subsequent short-term adjuvant androgen deprivation therapy

deprivation therapy （ADT） is a standard treatment for metastatic, recurrent and locally advanced prostate cancer （PCa）. The aim of this study is to investigate the timing and extent of testosterone recovery in clinically localized PCa patients treated with radical prostatectomy （RP） and subsequent short-term adjuvant ADT. A total of 95 localized PCa patients underwent RP and 9-month adjuvant ADT were included in this prospective study. Serum testosterone level was measured before adjuvant ADT, at ADT cessation, and at 1, 3, 6, 9 and 12 months after cessation of ADT. A Cox proportional hazards model was used to assess variables associated with the ti me of testosterone normalization. The results showed that median patient age was 67 years and median testosterone level before adjuvant ADT was 361 （230-905） ng d1-1. All patients finished 9-month adjuvant ADT and achieved castrate testosterone level. At 3 months after ADT cessation, testosterone recovered to supracastrate level in 97.9% patients and to normal level in 36.9% patients. The percentage of patients who recovered to normal testosterone level increased to 66.3%, 86.3% and 92.6% at 6, 9 and 12 months, respectively. Cox regression model found that higher baseline testosterone level （ 300 ng dl- 1） was the only variable associated with a shorter time to testosterone normalization （hazard ratio： 1.98; P -- 0.012）. In conclusion, in most patients, testosterone recovered to supracastrate level at 3 months and to normal level at 12 months after 9-month adjuvant ADT cessation. Patients with higher baseline testosterone level need shorter time of testosterone normalization.

Preclinical therapy of benign prostatic hyperplasia with neuropeptide hormone antagonists

Benign prostatic hyperplasia(BPH)is a pathologic condition of the prostate described as a substantial increase in its number of epithelial and stromal cells.BPH may significantly reduce the quality of life due to the initiation of bladder outlet obstruction and lower urinary tract syndromes.Current medical therapies mostly consist of inhibitors of 5α-reductase orα1-adrenergic blockers;their efficacy is often insufficient.Antagonistic analogs of neuropeptide hormones are novel candidates for the management of BPH.At first,antagonists of luteinizing hormone-releasing hormone(LHRH)have been introduced to the therapy aimed to reduce serum testosterone levels.However,they have also been found to produce an inhibitory activity on local LHRH receptors in the prostate as well as impotence and other related side effects.Since then,several preclinical and clinical studies reported the favorable effects of LHRH antagonists in BPH.In contrast,antagonists of growth hormone-releasing hormone(GHRH)and gastrin-releasing peptide(GRP)have been tested only in preclinical settings and produce significant reduction in prostate size in experimental models of BPH.They act at least in part,by blocking the action of respective ligands produced locally on prostates through their respective receptors in the prostate,and by inhibition of autocrine insulin-like growth factors-Ⅰ/Ⅱand epidermal growth factor production.GHRH and LHRH antagonists were also tested in combination resulting in a cumulative effect that was greater than that of each alone.This article will review the numerous studies that demonstrate the beneficial effects of antagonistic analogs of LHRH,GHRH and GRP in BPH,as well as suggesting a potential role for somatostatin analogs in experimental therapies.

An Evolutionary Approach for Personalized Therapy in Multiple Myeloma

Most patients with multiple myeloma (MM) respond well to initial therapy, but invariably relapse due to evolution of resistant phenotypes. Here we examine the evolutionary dynamics of proliferation of resistant MM phenotypes during therapy. By applying computational models to data from three clinical trials for newly diagnosed MM patients, we have quantified the size and level of chemoresistance of subpopulations within the tumor burden in 124 patients, prior to and during therapy. Subsequently, we used the computational models to explore an alternative strategy of “adaptive therapy” (AT), which includes defined treatment holidays, to improve the duration of “controlled disease” (CD). Simulations showed that AT could prolong CD in all three trials: 50.0% vs. 11.1% 50-month CD for a single agent approach in older adults (P = 0.0123), 80.4% vs. 58.8% 60-month CD for a multi-agent bortezomib based therapy (P = 0.0082), and 54.0% vs. 24.0% 60-month CD for a multi-agent lenalidomide based therapy (P < 0.0001). Increases in duration of CD resulted from the stabilization of tumor burden, which in turn would delay the growth of chemoresistant sub-populations in patients with partial (PR), or very good partial response (VGPR). These computational algorithms suggest that AT may provide an alternative and feasible therapeutic management strategy in MM.

Photothermal and Chemotherapy Combined Therapy of B-CuS-DOX Based on/pH Dual Stimulation

Single chemotherapy is difficult to meet the needs of tumor cure. Photothermia combined with chemotherapy is anew and effective anti-tumor therapy. However, the drug loading of nanoparticles and increase in performance of photothermalconversion limits the therapeutic effect of combination therapy. In this study, two-dimensional boron (boron, B) nanoparticles wereprepared by ultrasonic exfoliation, and copper sulfide (CuS) nanoparticles and doxorubicin (DOX) were grown on the surface ofthe nanoparticles to form B-CuS-DOX nanoparticles. B-CuS carrier has high DOX drug loading capacity (864mg/g) and goodphotothermal conversion performance (photothermal conversion efficiency at 808nm is 55.8%). At the same time, it can achievedrug release and good photothermal response at near infrared and pH. The nanoparticles designed in this study are expected toprovide an effective chemotherapy-photothermal therapy strategy for tumor therapy in vivo.

Low Releasing Mitomycin C Molecule Encapsulated with Chitosan Nanoparticles for Intravesical Installation

The aim of this investigation is preparation of Mitomycin-C encapsulated with chitosan nanoparticles synthesis using ionic gelation technique for intravesical controlled drug delivery systems. This study was conducted in vitro. Cumulative amount of drug released from the nanoparticles was calculated. Mitomycin-C release studies were examined for different pH values. During the drug loading and release studies, initial amount of drug was changed (i.e., 0.5, 1.25 and 2.5 mg) to get different release profiles and the release studies were repeated (n = 6). The loading efficiencies of Mitomycin-C with three different initial concentrations 0.5mg/ml, 1.25 mg/ml and 2.5 mg/ml into chitosan nanoparticles were 54.5%, 47.1% and 36.4%, respectively. For different pH values, the cumulative releases of Mitomycin-C from chitosan nanoparticles were 47% and 53% for pH 6.0 and 7.4, respectively (p < 0.01). For different drug doses, the cumulative releases of Mitomycin-C (MMC) from Chitosan nanoparticles were 44%, 53% and 65% for 0.5 mg/mL, 1.25 mg/mL and 2.5 mg/mL respectively (p < 0.01). The anticancer activity of Mitomycin-C loaded chitosan nanoparticles was measured in T24 bladder cancer cell line in vitro, and the results revealed that the 2.5 MMC coated Chitosan nanoparticles had better tumor cells decline activity. From this investigation, we conclude that the drug encapsulated synthesized chitosan nanoparticles possess a high ability to be used as pH and dose responsive drug delivery system. This systematic investigation demonstrates a promising future for the intravesical installation in treatment of the superficial bladder cancer.

情绪释放疗法联合药物缓解混合痔手术病人术后疼痛的效果观察

目的:探讨对混合痔手术病人采取情绪释放疗法联合药物干预的临床应用价值及对缓解其术后疼痛的效果。方法:选取2021年1月—2022年12月我院收治的混合痔手术病人70例,随机分为对照组及研究组,各35例。对照组采取常规药物干预,研究组采取情绪释放疗法联合药物干预。比较两组术后不同时点的疼痛水平、疼痛缓解效果、凝血指标、并发症发生情况。结果:研究组术后24 h、36 h、72 h、7 d疼痛视觉模拟评分(VAS)均低于对照组(P<0.05);研究组疼痛缓解总有效率高于对照组(P<0.05);研究组凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)均长于对照组(P<0.05);研究组术后并发症发生率低于对照组(P<0.05)。结论:对混合痔手术病人采取情绪释放疗法联合药物干预,术后疼痛缓解效果显著,可改善凝血功能,减少并发症,促进术后康复。

小切口正中神经松解术联合穴位注射序贯疗法治疗腕管综合征的效果

目的:探讨小切口正中神经松解术联合穴位注射序贯疗法治疗腕管综合征(CTS)的效果。方法:选择2021年1月—2023年1月钦州市第二人民医院收治的103例CTS患者作为研究对象。按照随机数表法分为对照组(n=52)和观察组(n=51),两组均进行小切口正中神经松解术治疗,对照组术后口服神经营养素药物治疗,观察组术后采用穴位注射序贯法治疗。比较两组治疗效果、腕关节综合征Levine评分及正中神经肌电图指标[感觉传导速度(SCV)、感觉神经动作电位波幅(SNAP)、运动神经末端运动潜伏期(DML)]。结果:观察组总有效率为98.00%,高于对照组的80.00%,差异有统计学意义(P<0.05)。治疗6个月后,两组严重程度、功能状态评分低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗6个月后,两组SCV、SNAP均高于治疗前,DML低于治疗前,且观察组SCV、SNAP高于对照组,DML低于对照组,差异有统计学意义(P<0.05)。结论:小切口正中神经松解术联合穴位注射序贯疗法治疗CTS可有效提高其治疗效果,改善患者腕关节功能,促进神经恢复。

情绪释放疗法联合授权赋能教育在白内障高龄病人中的应用

目的:探讨情绪释放疗法联合授权赋能教育应用于白内障高龄病人中的效果。方法:选择2022年1月—2023年3月医院行手术治疗的80例白内障高龄病人为研究对象,依组间基本特征均衡可比原则分为对照组、观察组,每组40例。对照组接受常规干预,观察组在此基础之上加用情绪释放疗法与授权赋能联合干预,比较两组病人干预前后正负性情绪评分、疾病不确定感评分、生理应激指标与并发症发生率。结果:干预后观察组病人正性情绪评分高于对照组(P<0.05),负性情绪评分、疾病不确定感评分低于对照组(P<0.05),生理应激指标、并发症发生率低于对照组(P<0.05)。结论:将情绪释放疗法联合授权赋能教育应用于白内障高龄病人中,有利于改善其负性情绪、疾病不确定感、生理应激指标,降低其并发症发生率。

凉血十味片联合硝苯地平缓释片治疗原发性高血压性视网膜病变临床观察

目的探究凉血十味片联合硝苯地平缓释片治疗原发性高血压性视网膜病变(HR)的疗效及安全性。方法选取HR患者100例,按照随机数字表法分为治疗组(凉血十味片+硝苯地平缓释片)及对照组(硝苯地平缓释片),各50例,对比2组临床疗效。结果治疗组总有效率高于对照组(P<0.05);治疗后,治疗组血压、视力、眼底改变情况、眼底荧光素血管造影情况、中医证候积分均优于对照组(P<0.05)。结论凉血十味片联合硝苯地平缓释片治疗HR疗效确切,能有效提升患者视力,提高患者视觉质量,且无不良反应,安全有效。